Biocure Technology Valuation

Q: What is the Fair Price of CURE.X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CURE.X (CA$0.03) is trading below our estimate of [[fair value]] (CA$1.02)

Is CURE.X undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CURE.X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CURE.X (CA$0.03) is trading below our estimate of fair value (CA$1.02)

Significantly Below Fair Value: CURE.X is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CURE.X?

Key metric: As CURE.X is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CURE.X. This is calculated by dividing CURE.X's market cap by their current book value.
What is CURE.X's PB Ratio?
PB Ratio	0.2x
Book	CA$1.55m
Market Cap	CA$313.34k

CURE.X key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CURE.X's PB Ratio compare to its peers?

The above table shows the PB ratio for CURE.X vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	16.7x
GTTX GeneTether Therapeutics	2.6x	n/a	CA$3.9m
ENBI Entheon Biomedical	5x	n/a	CA$1.2m
VXL Vaxil Bio	1.7x	n/a	CA$1.4m
NAV NAVCO Pharmaceuticals	57.4x	n/a	CA$1.1m
CURE.X Biocure Technology	0.2x	n/a	CA$313.3k

Price-To-Book vs Peers: CURE.X is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (16.7x).

Price to Book Ratio vs Industry

How does CURE.X's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap
Industry Avg.	2.6x	31.5%
CURE.X Biocure Technology	0.2x	n/a	US$224.17k
QPT Quest PharmaTech	0.3x	n/a	US$3.63m

No more companies available in this PB range

2 Companies		Estimated Growth	Market Cap
Industry Avg.	2.6x	31.5%
CURE.X Biocure Technology	0.2x	n/a	US$224.17k

No more companies

Price-To-Book vs Industry: CURE.X is good value based on its Price-To-Book Ratio (0.2x) compared to the Canadian Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is CURE.X's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CURE.X PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CURE.X's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$129.5m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

30.1%

-38.9%

Verano Holdings

CA$765.1m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

-14.8%

-65.2%

Decibel Cannabis

CA$28.8m

An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.

CA$0.065

-53.6%